ライフサイエンスコーパス: adenomatous polyposis coli

1 adenoma growth in the context of mutant Apc (adenomatous polyposis coli).

2 ducin repeat-containing protein 2), and APC (adenomatous polyposis coli).

3 ng glycogen synthase kinase 3beta, axin, and adenomatous polyposis coli.

4 genic mechanism associated with mutations in Adenomatous Polyposis Coli.

5 urden in a murine tumor model of spontaneous adenomatous polyposis coli.

6 In addition we identified adenomatous polyposis coli 1 (APC1) as an interaction pa

7 Germline specific overexpression of Adenomatous Polyposis Coli 2 (APC2) rescued GSC loss in

8 sly in germ cells for proper localization of Adenomatous polyposis coli 2 and E-cadherin at the hub-G

9 ation of the centrosomal proteins Ninein and adenomatous polyposis coli abolished this bias.

10 tive regulators of beta-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor pro

11 G-protein signaling (RGS) domain that binds adenomatous polyposis coli and Galpha subunits, thereby

12 member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g.

13 of the postsynaptic density, among them the adenomatous polyposis coli, and 2) proteins with express

14 aditionally attributed to mutations in Axin, adenomatous polyposis coli, and beta-catenin that lead t

15 generally lacked differentiation markers and adenomatous polyposis coli antigen.

16 e conditionally expressed a mutant allele of adenomatous polyposis coli (APC(cKO)) in murine uterine

17 al crypt, augmenting CRC tumorigenesis in an adenomatous polyposis coli (APC(Delta14/+)) mouse model.

18 n on chronic hypoxia-induced PH, we used the adenomatous polyposis coli (Apc(Min/+)) mouse, where red

19 ve shown that a cancer causing truncation in adenomatous polyposis coli (APC) (APC(1-1450)) dominantl

20 as a binding partner of the tumor suppressor adenomatous polyposis coli (APC) [1]; however, the signi

21 The tumor suppressor Adenomatous polyposis coli (APC) affects the function of

22 induced by the rare inheritance of a mutant adenomatous polyposis coli (Apc) allele.

23 ministering LPA to mice heterozygous for the adenomatous polyposis coli (Apc) allele.

24 contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathoge

25 ested that specific GSK3 substrates, such as adenomatous polyposis coli (APC) and collapsin response

26 we show that two tumor suppressor proteins, adenomatous polyposis coli (APC) and Dlg1-SAP97, are req

27 wo microtubule plus end-associated proteins, adenomatous polyposis coli (APC) and EB1, providing a po

28 onal and transcriptional mechanisms and that adenomatous polyposis coli (APC) and GSK3beta, which are

29 expression of the gut tumor suppressor gene adenomatous polyposis coli (Apc) and its role in the oli

30 e, we report that mPar3 forms a complex with adenomatous polyposis coli (APC) and kinesin superfamily

31 Finally, CBC stem cells deficient in adenomatous polyposis coli (Apc) and Math1 were able to

32 associate with the tumor suppressor protein adenomatous polyposis coli (APC) and p150glued, a compon

33 ed by the colorectal cancer tumor suppressor adenomatous polyposis coli (APC) and that KLF4 repressed

34 ther, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose poly

35 nce microscopy to image the tumor suppressor adenomatous polyposis coli (APC) and the formin mDia1 du

36 firmed an expected loss in the expression of adenomatous polyposis coli (APC) and the transcriptional

37 First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stom

38 polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP

39 As in mammals, loss of adenomatous polyposis coli (APC) causes Drosophila intes

40 Here we find that the tumor suppressor adenomatous polyposis coli (APC) controls microtubule ta

41 C57BL/6J mice carrying the Min allele of Adenomatous polyposis coli (Apc) develop numerous adenom

42 Mutations in adenomatous polyposis coli (APC) disrupt regulation of W

43 rectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their

44 show here that the tumor-suppressor protein adenomatous polyposis coli (APC) functions in localizing

45 As Adenomatous Polyposis Coli (APC) functions in many of th

46 mice bearing a heterozygote mutation in the adenomatous polyposis coli (APC) gene (Apc(Min/+) mice).

47 ted gene-targeted pigs with mutations in the adenomatous polyposis coli (APC) gene (APC) that are ort

48 The adenomatous polyposis coli (Apc) gene also plays an impo

49 of these models involve modification of the adenomatous polyposis coli (Apc) gene and are excellent

50 ased in human cells with deficiencies in the adenomatous polyposis coli (APC) gene and in cells stimu

51 We show that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent act

52 Mutations in the adenomatous polyposis coli (APC) gene are associated wit

53 Patients with mutations in the Adenomatous Polyposis Coli (APC) gene are at increased r

54 Somatic mutations of the adenomatous polyposis coli (APC) gene are initiating eve

55 Mutations in the adenomatous polyposis coli (APC) gene are pivotal in col

56 Genetic mutations in the adenomatous polyposis coli (APC) gene are thought to cau

57 Mutations in the human adenomatous polyposis coli (APC) gene are thought to ini

58 l cancer cell lines bearing mutations on the adenomatous polyposis coli (APC) gene as a model of FAP-

59 The adenomatous polyposis coli (APC) gene encodes APC tumour

60 using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine rena

61 Since the Adenomatous Polyposis Coli (APC) gene is mutated in the

62 The Adenomatous Polyposis Coli (APC) gene is mutated in the

63 The adenomatous polyposis coli (APC) gene is mutated within

64 Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well

65 Adenomatous polyposis coli (APC) gene mutations have bee

66 Mutations in the adenomatous polyposis coli (APC) gene occur in the vast

67 ost colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the beta-cateni

68 The adenomatous polyposis coli (APC) gene plays, among other

69 The adenomatous polyposis coli (APC) gene product is mutated

70 letion in mice with inactivating mutation of adenomatous polyposis coli (APC) gene reduces intestinal

71 Mutations in the adenomatous polyposis coli (APC) gene result in uncontro

72 ssf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate inte

73 ization of beta-catenin or defective for the adenomatous polyposis coli (APC) gene to reinvestigated

74 Mutations in the Adenomatous Polyposis Coli (APC) gene up-regulate Wnt si

75 n the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult b

76 The adenomatous polyposis coli (APC) gene, a member of the W

77 intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to ac

78 requently bear inactivating mutations of the adenomatous polyposis coli (APC) gene, whose product is

79 velop through loss of normal function of the Adenomatous polyposis coli (APC) gene.

80 g, in particular, tumor suppressors TP53 and adenomatous polyposis coli (APC) gene.

81 imiting mutations in human CRC occurs in the adenomatous polyposis coli (APC) gene.

82 omas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene.

83 nt in mice with heterozygous mutation in the adenomatous polyposis coli (APC) gene.

84 ontinues to be dominated by mutations in the adenomatous polyposis coli (APC) gene.

85 estinal neoplasia caused by mutations of the adenomatous polyposis coli (Apc) gene.

86 cancer cases due to somatic mutations in the adenomatous polyposis coli (APC) gene.

87 e generated mice lacking the beta-catenin or adenomatous polyposis coli (Apc) genes in osteoblasts.

88 here that the mouse tumor suppressor protein adenomatous polyposis coli (APC) has a role in AChR clus

89 The adenomatous polyposis coli (APC) I1307K allele is found

90 criptional and epigenetic changes induced by adenomatous polyposis coli (Apc) inactivation in intesti

91 Wnt/beta-catenin pathway signaling following adenomatous polyposis coli (APC) inactivation.

92 Mutations in the tumor suppressor adenomatous polyposis coli (APC) initiate most colon can

93 The tumor suppressor adenomatous polyposis coli (APC) is a crucial regulator

94 ncluding the brain, and the tumor suppressor adenomatous polyposis coli (APC) is a key negative regul

95 Adenomatous polyposis coli (APC) is a large multidomain

96 Adenomatous polyposis coli (APC) is a microtubule plus-e

97 Adenomatous polyposis coli (APC) is a multifunctional tu

98 The tumor suppressor Adenomatous polyposis coli (APC) is a negative regulator

99 Mutational inactivation of adenomatous polyposis coli (APC) is an early event in co

100 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

101 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

102 ASE of adenomatous polyposis coli (APC) is associated with path

103 Adenomatous polyposis coli (APC) is best known for its c

104 Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initia

105 The tumor suppressor adenomatous polyposis coli (APC) is frequently mutated i

106 The tumor suppressor adenomatous polyposis coli (APC) is implicated in regula

107 The tumor suppressor protein adenomatous polyposis coli (APC) is multifunctional - it

108 Adenomatous polyposis coli (APC) is mutated in colon can

109 Adenomatous polyposis coli (APC) is one such MAP with a

110 Loss of tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

111 aling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

112 ore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by

113 Today, the tumor suppressor adenomatous polyposis coli (APC) may have the same compl

114 te that intestinal epithelial suppression of adenomatous polyposis coli (Apc) mitigates RIGS lethalit

115 Here, we show that adenomatous polyposis coli (APC) modulates microtubule (

116 vessels in RIP-Tag2 transgenic mouse tumors, adenomatous polyposis coli (apc) mouse adenomas, and imp

117 ects of daily oral administration of HFCS in adenomatous polyposis coli (APC) mutant mice, which are

118 We report that adenomatous polyposis coli (APC) mutant zebrafish harbor

119 esis that initiation of colorectal cancer by adenomatous polyposis coli (APC) mutation is mediated by

120 Adenomatous polyposis coli (APC) mutation is the most co

121 gastric cancer cells even in the presence of adenomatous polyposis coli (Apc) mutation.

122 Adenomatous polyposis coli (APC) mutations are linked to

123 In this study, we show that adenomatous polyposis coli (APC) mutations found in huma

124 nt/beta-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in app

125 Individuals with heterozygous germline adenomatous polyposis coli (APC) mutations or familial a

126 The tumor suppressor Adenomatous polyposis coli (APC) negatively regulates Wn

127 Depletion of the tumor suppressors adenomatous polyposis coli (APC) or Axin dramatically in

128 (CRCs), an initiating mutation occurs in the adenomatous polyposis coli (APC) or beta-catenin gene, a

129 n that have been associated with loss of the adenomatous polyposis coli (APC) or constitutive activat

130 d glycogen synthase kinase 3beta (GSK-3beta)/adenomatous polyposis coli (APC) pathways.

131 Adenomatous polyposis coli (APC) plays a critical role i

132 The tumor suppressor adenomatous polyposis coli (APC) plays a critical role i

133 The tumor suppressor Adenomatous polyposis coli (APC) plays a key role in reg

134 nestin expressing NeuN positive neurons and adenomatous polyposis coli (APC) positive mature oligode

135 ver beta-catenin/E-cadherin and beta-catenin/adenomatous polyposis coli (APC) PPIs.

136 In interphase cells, the adenomatous polyposis coli (APC) protein accumulates on

137 ibition of GSK-3beta and accumulation of the adenomatous polyposis coli (APC) protein at the plus end

138 ere, we report that the expression status of adenomatous polyposis coli (APC) protein determines the

139 The adenomatous polyposis coli (APC) protein functions as a

140 The role of wild-type adenomatous polyposis coli (APC) protein in native epith

141 Loss of the adenomatous polyposis coli (APC) protein is a common ini

142 Adenomatous polyposis coli (APC) protein is a large tumo

143 The adenomatous polyposis coli (APC) protein is inactivated

144 rating cells, and induces the interaction of adenomatous polyposis coli (Apc) protein with the plus e

145 CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabili

146 Fap1 also interacts with the adenomatous polyposis coli (Apc) protein, but the functi

147 des the kinases, beta-catenin, axin, and the Adenomatous Polyposis Coli (APC) protein.

148 inked to deficiencies in mismatch repair and adenomatous polyposis coli (APC) proteins, diet, inflamm

149 ing a knockout allele in the gatekeeper gene Adenomatous polyposis coli (Apc) recapitulates familial

150 The tumor suppressor protein adenomatous polyposis coli (APC) regulates cell protrusi

151 Adenomatous polyposis coli (APC) regulates the activity

152 is functionally important for cell migration.Adenomatous polyposis coli (APC) regulates the localizat

153 gene targeting in mice, we demonstrate that adenomatous polyposis coli (APC) serves an essential fun

154 The tumor suppressor protein adenomatous polyposis coli (APC) stabilizes microtubules

155 ne such pathway the tumor-suppressor protein adenomatous polyposis coli (APC) targets RNAs to cell pr

156 Here, we have defined a repeat sequence in adenomatous polyposis coli (APC) that binds to EB1's COO

157 ting factor-responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cyt

158 Binding of adenomatous polyposis coli (APC) to the microtubule plus

159 In turn, KIF17 participates in localizing adenomatous polyposis coli (APC) to the plus ends of a s

160 The adenomatous polyposis coli (APC) tumor suppressor forms

161 Acquired or inherited mutations in the adenomatous polyposis coli (APC) tumor suppressor gene a

162 The adenomatous polyposis coli (APC) tumor suppressor gene e

163 The Adenomatous Polyposis Coli (APC) tumor suppressor gene i

164 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene i

165 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene s

166 cells lines with truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor gene t

167 found in patients harboring mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.

168 The Adenomatous Polyposis Coli (APC) tumor suppressor is a m

169 The adenomatous polyposis coli (APC) tumor suppressor is a m

170 Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is fre

171 The adenomatous polyposis coli (APC) tumor suppressor is ina

172 The adenomatous polyposis coli (Apc) tumor suppressor is inv

173 ce with IEC-specific allelic deletion of the adenomatous polyposis coli (Apc) tumor suppressor locus,

174 The adenomatous polyposis coli (APC) tumor suppressor protei

175 atase 2A (PP2A) and must be protected by the adenomatous polyposis coli (APC) tumor suppressor protei

176 Mutation of the adenomatous polyposis coli (APC) tumor suppressor stabil

177 rcinomas contain truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor, a neg

178 in signaling is negatively controlled by the adenomatous polyposis coli (APC) tumor suppressor, which

179 lators of nucleocytoplasmic shuttling of the adenomatous polyposis coli (APC) tumor suppressor.

180 calculating the in vivo mutation rate of the adenomatous polyposis coli (APC) tumor-suppressor gene i

181 ollows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and a

182 RNAs in the granules associate with the adenomatous polyposis coli (APC) tumour suppressor and t

183 Mutations in the adenomatous polyposis coli (APC) tumour suppressor are t

184 Mutations in Adenomatous polyposis coli (APC) underlie familial adeno

185 Mutations in adenomatous polyposis coli (APC) underlie the earliest s

186 In this study, the tumor suppressor protein adenomatous polyposis coli (APC) was found to be importa

187 We found that the tumor suppressor adenomatous polyposis coli (APC) was required for microt

188 These mice were crossed with adenomatous polyposis coli (Apc)(min/+) mice, or given a

189 ne the genetic relationship between MPC1 and Adenomatous polyposis coli (APC), a key tumor suppressor

190 Inactivating mutations within adenomatous polyposis coli (APC), a negative regulator o

191 Adenomatous polyposis coli (APC), a protein with both tu

192 approaches suggest that the tumor suppressor adenomatous polyposis coli (APC), a regulator of Wnt sig

193 Adenomatous polyposis coli (APC), a tumor suppressor com

194 Adenomatous polyposis coli (Apc), a tumor suppressor gen

195 Adenomatous polyposis coli (APC), a tumor suppressor gen

196 Specific site of CpG islands of adenomatous polyposis coli (APC), a well studied tumor s

197 The tumor suppressor adenomatous polyposis coli (APC), an essential negative

198 atenin destruction complex components Axin1, adenomatous polyposis coli (APC), and GSK3beta were also

199 ein complex containing the proteins axin and adenomatous polyposis coli (APC), both of which bind dir

200 forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), casein kinase 1alpha (

201 Rac1-specific exchange factor stimulated by adenomatous polyposis coli (APC), contributing to colore

202 Together with its direct binding partner adenomatous polyposis coli (APC), EB1 can stabilize micr

203 Mutations in known driver genes [e.g., adenomatous polyposis coli (APC), KRAS, or PIK3CA] found

204 Individual crypt adenomatous polyposis coli (APC), p53, K-RAS, and 17p lo

205 in acromegaly patients induced colon p53 and adenomatous polyposis coli (APC), reversing progrowth GH

206 e designed against beta-catenin (Ctnnb1) and adenomatous polyposis coli (Apc), two commonly mutated g

207 ical Wnt signaling by targeting the gene for Adenomatous Polyposis Coli (Apc), which controls Wnt sig

208 e, we show that the tumor suppressor protein adenomatous polyposis coli (APC), which is a known MT-as

209 its expression and activity using models of adenomatous polyposis coli (APC)- and chemotherapy-induc

210 Two adenomatous polyposis coli (APC)-dependent proteasomal d

211 eracts with beta-catenin through a conserved adenomatous polyposis coli (APC)-like domain.

212 Expression of eIF6 in adenomatous polyposis coli (APC)-mutant colon cancer cel

213 ulation and epithelial over-proliferation in Adenomatous polyposis coli (APC)-mutated intestine.

214 o develop colitis-associated and spontaneous adenomatous polyposis coli (APC)-related tumors of the i

215 iously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (

216 P), Skp1, transducin beta-like 1 (TBL1), and adenomatous polyposis coli (APC).

217 n of a microtubule plus end binding protein, adenomatous polyposis coli (APC).

218 runcating mutations in the tumor suppressor, adenomatous polyposis coli (APC).

219 RC) through mutation of the tumor suppressor Adenomatous Polyposis Coli (APC).

220 glycogen synthase kinase-3beta, axin-1, and adenomatous polyposis coli (APC).

221 to the inactivation of the tumor suppressor adenomatous polyposis coli (APC).

222 by aberrant function of the tumor suppressor Adenomatous polyposis coli (Apc).

223 ation suppresses beta-catenin activity in an adenomatous polyposis coli (APC)/glycogen synthase kinas

224 s; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)min/+ mice.

225 We analyzed adenomatous polyposis coli (Apc)min/+/Sigirr-/- mice for

226 py, FRAP, live cell imaging, and a mutant of Adenomatous polyposis coli (APC-m4) defective in actin n

227 vilVEGF1 mice were bred to Min mice (adenomatous polyposis coli [APC] +/-).

228 I, IGF2; tumor suppressor candidate 33, N33; adenomatous polyposis coli, APC; mut-L homolog 1, MLH1;

229 Arm is targeted for proteolysis by the Axin/Adenomatous polyposis coli (Apc1 and Apc2)/Zeste-white 3

230 a-catenin pathway mutations, such as loss of adenomatous polyposis coli, are insensitive to this nove

231 atenin and the destruction complex component adenomatous polyposis coli at a similar SLS motif to the

232 e glycogen synthase kinase 3beta (GSK3beta)- adenomatous polyposis coli-axin-mediated degradation pat

233 Because mutations in adenomatous polyposis coli, beta-catenin and other compo

234 kers associated with colon cancer, including adenomatous polyposis coli, beta-catenin, p53, c-myc, cy

235 intestinal tumors driven by mutations in the adenomatous polyposis coli/beta-catenin pathway and acti

236 f cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

237 ble in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

238 erived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon

239 V integration site family (WNT)/beta-catenin/adenomatous polyposis coli (CTNNB1/APC) pathway has been

240 In the context of APC (adenomatous polyposis coli) deficiency (Apc(Min/+) mice)

241 otubule organization and capture dynamics in adenomatous polyposis coli-deficient radial progenitors.

242 e intestinal neoplasia (Min) mutation of the adenomatous polyposis coli gene (Apc) and homozygous for

243 By using mice with germline mutations in the adenomatous polyposis coli gene (Apc) and/or DNA mismatc

244 Mutations in the adenomatous polyposis coli gene (Apc) are a major driver

245 t human colorectal cancers, mutations in the adenomatous polyposis coli gene (APC) or CTNNB1 constitu

246 as associated with reduced expression of the adenomatous polyposis coli gene (APC).

247 iation domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in his

248 Mice carrying and non-sense mutation in Adenomatous polyposis coli gene at site R850, which desi

249 olyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by deve

250 sis kindreds harboring an identical germline adenomatous polyposis coli gene mutation.

251 its other negative regulators, such as axin, adenomatous polyposis coli gene product (APC), and glyco

252 eta-catenin by inhibiting its binding to the adenomatous polyposis coli gene product and subsequent g

253 in, where carrier proteins like axin and the adenomatous polyposis coli gene product APC interact wit

254 comparatively rare missense variants in the adenomatous polyposis coli gene, which is responsible fo

255 eficient mice carrying the Min allele of the adenomatous polyposis coli gene.

256 and compared to control mice carry wildtype Adenomatous polyposis coli gene.

257 t is caused by inactivating mutations in the Adenomatous polyposis coli gene.

258 g in T cell lineages by deletion of the Apc (adenomatous polyposis coli) gene causes spontaneous T ce

259 and function through Disheveled (Dvl), Axin, adenomatous polyposis coli, glycogen synthase kinase 3be

260 -catenin pathway regulatory genes, including adenomatous polyposis coli, GSK3beta, axin 1, beta-caten

261 olocalizes with the tumor suppressor protein adenomatous polyposis coli in the TJs of epithelial cell

262 alignancies due to inactivating mutations of adenomatous polyposis coli (in colorectal cancer) or act

263 nction of the tumor suppressor protein, APC (adenomatous polyposis coli), in the regulation of base e

264 mutation of the Wnt repressor APC (encoding adenomatous polyposis coli) leads to a state of aberrant

265 that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of bet

266 ted signaling and glycogen synthase kinase-3/adenomatous polyposis coli-mediated beta-catenin activat

267 ence in normal intestinal homeostasis and in adenomatous polyposis coli-mediated tumorigenesis.

268 Crossing Tfam(+/-) mice to the adenomatous polyposis coli multiple intestinal neoplasia

269 Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/+) mice, which

270 Inherited and somatic mutations in the adenomatous polyposis coli occur in most colon cancers,

271 RC) harboring functional mutations in either adenomatous polyposis coli or beta-catenin.

272 ling induced by loss of the tumor suppressor adenomatous polyposis coli or casein kinase 1alpha uncov

273 Additional examination of one or more of the adenomatous polyposis coli, p14ARF, p16INK4a, or death a

274 Most information about the roles of the adenomatous polyposis coli protein (APC) and its binding

275 at RNAi-mediated depletion of two kMAPs, the adenomatous polyposis coli protein (APC) and its binding

276 olding protein Axin and the tumor suppressor adenomatous polyposis coli protein (APC) are critical co

277 We recently identified adenomatous polyposis coli protein (APC) as a key regula

278 Here we report that the tumour suppressor adenomatous polyposis coli protein (APC) directs the loc

279 We propose that adenomatous polyposis coli protein (APC) is a key coordi

280 have bi-allelic mutations in APC2, encoding adenomatous polyposis coli protein 2.

281 ixed disulfides with both beta4-spectrin and adenomatous polyposis coli protein in the cytosol.

282 n from Mlp of a region similar to one in the adenomatous polyposis coli protein involved in EB1 bindi

283 ows that the actin-nucleating ability of the adenomatous polyposis coli protein is required for disas

284 We had shown that the APC (adenomatous polyposis coli) protein controls localizatio

285 versely, RNAi of the beta-catenin antagonist adenomatous polyposis coli results in the regeneration o

286 However, little is known about adenomatous polyposis coli's (APC's) role in the mammali

287 W480 cells stably transformed with wild-type adenomatous polyposis coli showed decreased beta-catenin

288 on, and beta-catenin, a component of the Wnt-adenomatous polyposis coli signaling pathway, contribute

289 cognized a different autoantigen, except for adenomatous polyposis coli that was recognized by sera o

290 ectly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wing

291 Germ line mutations in the Adenomatous polyposis coli tumor suppressor gene cause a

292 syndrome caused by germline mutations in the adenomatous polyposis coli tumor suppressor gene.

293 he microtubule motor cytoplasmic dynein, the adenomatous polyposis coli tumor suppressor protein (APC

294 centrosome function and cortically localized Adenomatous Polyposis Coli tumor suppressor protein to o

295 Mutations in the APC (adenomatous polyposis coli) tumor suppressor gene cause

296 The APC gene encodes the adenomatous polyposis coli tumour suppressor protein, ge

297 her beta-catenin activation or loss of APC - adenomatous polyposis coli) upon expression of CRE recom

298 All patients were tested for the adenomatous polyposis coli variants I1307K and E1317Q, a

299 Inactivation of the tumor suppressor adenomatous polyposis coli, with the resultant activatio

300 Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates